What is the main business of Neomedic?

The main business activity of Neomedic focuses on activities of head office and holding companies, excluding financial holding companies.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on December 21, 2016.

Where is the headquarters located?

The headquarters is located at: Al. Gen. Tadeusza Bora-Komorowskiego 25C, 31-476 Kraków.

Who is on the management board?

The management board consists of: Paweł Grzegorz Piszczek (Member of the Management Board) and Tomasz Wiśniewski (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 2,541,500 (approx. $686,521).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

How much revenue was generated?

In 2024, the company generated total revenue of $7,623,562, representing an increase of 374.2% compared to 2023.

Is the company profitable?

Yes, the company recorded a net profit of $6,574,470 in 2024, representing a multi-fold increase compared to 2023.

What is the main operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to $532,933 in 2024, representing 44% of all operating expenses.

NeomedicS.A.

Activities of head office and holding companies, excluding financial holding companies

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2016-12-21

Share capital

2,541,500.00 PLN

Activity description

Grupa Neomedic runs the Ujastek Medical Center. It provides medical consultations and full laboratory and imaging diagnostics. The site emphasizes teamwork, safety, learning, and continuous improvement in patient care.

Registered address

al. Gen. Tadeusza Bora-Komorowskiego 25C, 31-476 Kraków, Poland

Website

grupaneomedic.pl

Electronic delivery address

AE:PL-30027-78059-CEFBD-25

Financials

Revenue history (in k)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 77 days for 2021). All were audited by a statutory auditor.

202514/07/2026
202410/07/2025
202316/07/2024
202220/06/2023
202130/09/2022
202028/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 6.98mMedianUSD 29.13kAverageUSD 6.02m

Net profit

This companyUSD 5.86mMedianUSD 323.92AverageUSD 827.95k

Operating costs

This companyUSD 1.25mMedianUSD 14.45kAverageUSD 4.71m

Assets

This companyUSD 68.60mMedianUSD 86.85kAverageUSD 17.30m

Industry

Website technology

Website

WordPress
Elementor

Analytics and marketing

Google Analytics
Google Tag Manager

Authorized Representatives

Paweł Grzegorz Piszczek – Management Board Member

Tomasz Wiśniewski – President of the Management Board

Manner of representation

The persons authorised to make declarations on behalf of the company are the President of the Management Board independently, as well as two members of the management board acting jointly.

Supervisory board

Dariusz Rodak – Supervisory Board Member

Paulina Lasocka Wysoczańska – Supervisory Board Member

Piotr Wojciechowski – Supervisory Board Member

Ownership

Owner
Abc Medicover Holdings B.v.

Beneficial owners

Person	Rights

Subsidiaries

Name	Share value	Stake
Centrum Medyczne Ujasteksp. z o.o.	1,579,956.78 USD	100%
Medikor IIIsp. z o.o.	10,804.97 USD	100%
Ujastek Inwestycjesp. z o.o.	676,661.26 USD	100%

Bank accounts

Registered as a VAT taxpayer on 2009-03-02.

ING Bank Śląski
55 1050 1575 1000 0024 9609 7136
ING Bank Śląski
61 1050 1445 1000 0024 5527 7885
ING Bank Śląski
21 1050 1445 1000 0023 6487 2180

Debt

No entries in the National Debtors Register (KRZ).

Public aid

4 public aid cases recorded, with a total value of $32,578.

Grant date	Purpose	Gross amount	Granting body
Sep 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$3,692$3,692	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,098$5,098	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,096$5,096	Prezes Zakładu Ubezpieczeń Społecznych

Competitors

	Name	Revenue	Website
	Grupa Nowy Szpital HoldingS.A.	$14,213,962.83	nowyszpital.pl
	OD SercaS.A.	$1,697,427.14	aptekaodserca.pl

Change history

Date	Event
2024-01-30	Share capital increase (185,000.00 PLN → 2,541,500.00 PLN)
2016-12-21	Entered in the register

FAQ

Last updated: 2026-10-04